<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231569</url>
  </required_header>
  <id_info>
    <org_study_id>301012CS4</org_study_id>
    <secondary_id>EudraCT No.: 2005-002119-26</secondary_id>
    <nct_id>NCT00231569</nct_id>
  </id_info>
  <brief_title>Dose-escalating Safety Study in Subjects on Stable Statin Therapy</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Doseâ€‘Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kastle Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kastle Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on
      Stable statin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in LDL-cholesterol from baseline</measure>
    <time_frame>From baseline measurement</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in apoB-100</measure>
    <time_frame>From baseline measurement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL plus LDL-cholesterol and LDL-cholesterol particle size and concentration</measure>
    <time_frame>From baseline measurement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios</measure>
    <time_frame>From baseline measurement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs, SAEs, physical examination data, vital signs, and laboratory analyzes</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading doses followed by weekly maintenance doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading doses followed by weekly maintenance doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading doses followed by weekly maintenance doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading doses followed by weekly maintenance doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading doses followed by weekly maintenance doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading doses followed by extended weekly maintenance doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading doses followed by extended weekly maintenance doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29</description>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29</description>
    <arm_group_label>Cohort E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85</description>
    <arm_group_label>Cohort F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85</description>
    <arm_group_label>Cohort G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On a stable dose of &gt;/= 40 mg Simvastatin or atorvastatin daily for &gt;/= 3 months prior
             to baseline and expected to remain on this dose for the remainder of the study

          -  LDL-cholesterol between 2.60 and 5.70 mmol/L (100 and 220 mg/dL), inclusive at
             screening

          -  Females not of childbearing potential.

        Exclusion Criteria:

          -  History of CHD or CHD-equivalent (such as diabetes mellitus, or another clinical form
             of atherosclerotic disease, e.g., peripheral arterial disease, abdominal aortic
             aneurysm, or symptomatic carotid artery disease)

          -  Fasting triglyceride &gt;2.26 mmol/L (200 mg/dL) at screening

          -  Any uncontrolled medical/surgical/psychiatric condition, including conditions that may
             predispose to secondary hypercholesterolemia

          -  Current diagnosis or known history of complement deficiency or abnormality

          -  A positive hepatitis B surface antigen or hepatitis C antibody, or a known positive
             HIV status

          -  Current diagnosis or known history of liver disease, or has an ALT &gt;ULN at screening

          -  Known history of fibromyalgia, myopathy, myositis, rhabdomyolysis, any unexplained
             muscle pain, or has a CPK &gt;ULN at screening

          -  Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin
             that has been adequately treated

          -  The advisability of a subject taking any prescription medication (apart from
             simvastatin or atorvastatin) within 6 weeks prior to screening should be discussed
             with the Isis Medical Monitor

          -  Subject unwilling to discontinue taking alternative/herbal medication for the duration
             of the study

          -  History of drug abuse within 2 years of screening

          -  Subject unwilling to limit alcohol consumption for the duration of the study: male
             subjects to a maximum of 3 drinks (30 g) per day, and &lt;12 drinks (120 g) per week;
             female subjects to a maximum of 2 drinks (20 g) per day, and &lt;8 drinks (80 g) per week

          -  Known allergy or hypersensitivity to simvastatin

          -  Undergoing or has undergone treatment with another investigational drug, biologic
             agent, or device within 3 months, or 3 half lives, prior to screening, whichever is
             longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <zip>2311 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Coporation</organization>
  </responsible_party>
  <keyword>LDL-cholesterol</keyword>
  <keyword>apoB-100</keyword>
  <keyword>apoB-48</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mipomersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

